These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 25339589)

  • 1. Neurotensin-like peptides as potential antipsychotics: modulation of the serotonin system.
    Kost NV; Meshavkin VK; Khashaba EY; Sokolov OY; Voevodina ME; Zolotarev YA; Andreeva LA; Myasoedov NF
    Bull Exp Biol Med; 2014 Oct; 157(6):738-41. PubMed ID: 25339589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neurotensin-like oligopeptides as potential antipsychotics: effect on dopamine system].
    Kost NV; Meshavkin VK; Batishcheva EIu; Sokolov OIu; Andreeva LA; Miasoedov NF
    Eksp Klin Farmakol; 2011; 74(10):3-6. PubMed ID: 22238978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies with new ergoline derivatives on the effects of central and peripheral 5-hydroxytryptamine receptors.
    Harhammer R; Schäfer U; Ott T
    Arzneimittelforschung; 1992 Oct; 42(10):1175-9. PubMed ID: 1472137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypotensive and antiaggregative effects of eugenosedin-B with serotonin and alpha/beta-adrenoceptor antagonistic activities in rats and human platelets.
    Shen KP; Chu LW; Hsieh SL; An LM; Chen IJ; Wu BN
    J Cardiovasc Pharmacol; 2008 Feb; 51(2):154-61. PubMed ID: 18287883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841.
    Krisch I; Bole-Vunduk B; Pepelnak M; Lavric B; Ocvirk A; Budihna MV; Sket D
    J Pharmacol Exp Ther; 1994 Oct; 271(1):343-52. PubMed ID: 7965734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
    Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
    Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors.
    Wong DT; Threlkeld PG; Robertson DW
    Neuropsychopharmacology; 1991 Aug; 5(1):43-7. PubMed ID: 1930610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
    Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
    J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties.
    Holthoewer D; Kirschbaum KM; Frisch J; Hiemke C; Schmitt U
    Pharmacopsychiatry; 2013 Jul; 46(5):175-80. PubMed ID: 23737243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of some calcium antagonists on aggregation by adrenalin and serotonin and on alpha-adrenoceptor radioligand binding in human platelets.
    Vinge E; Andersson TL; Larsson B
    Acta Physiol Scand; 1988 Jul; 133(3):407-16. PubMed ID: 2906509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of mu-CPP and mesulergine on dietary choices in deprived rats: possible mechanisms of their action.
    Antonatos S; Galanopoulou P
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan; 30(1):112-9. PubMed ID: 16242827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of linking bridge modifications on the antipsychotic profile of some phthalimide and isoindolinone derivatives.
    Norman MH; Minick DJ; Rigdon GC
    J Med Chem; 1996 Jan; 39(1):149-57. PubMed ID: 8568802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxazosin and serotonin (5-HT) receptor (1A, 2A, and 4) antagonists inhibit 5-HT-mediated human cavernosal contraction.
    Lau DH; Thompson CS; Bellringer JF; Thomas PJ; Mumtaz FH; Morgan RJ; Mikhailidis DP
    J Androl; 2006; 27(5):679-85. PubMed ID: 16728720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties.
    Bardin L; Kleven MS; Barret-Grévoz C; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1869-79. PubMed ID: 16237379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric modulation of 5-HT(1A) receptors by zinc: Binding studies.
    Barrondo S; Sallés J
    Neuropharmacology; 2009 Feb; 56(2):455-62. PubMed ID: 18951909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ketanserin (S2-receptor blocking agent), platelet activity and chronic alcoholism.
    Santini P; Ceccanti M; De Lorenzo A; Pisculli M; Di Giovanni MG; Cavaleri G; Attilia ML; Berbellini A
    Int J Clin Pharmacol Res; 1986; 6(1):73-6. PubMed ID: 2937746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cocaine acts on accumbens monoamines and locomotor behavior via a 5-HT2A/2C receptor mechanism as shown by ketanserin: 24-h follow-up studies.
    Broderick PA; Olabisi OA; Rahni DN; Zhou Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):547-57. PubMed ID: 15093963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
    Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
    Oka M; Noda Y; Ochi Y; Furukawa K; Une T; Kurumiya S; Hino K; Karasawa T
    J Pharmacol Exp Ther; 1993 Jan; 264(1):158-65. PubMed ID: 8093723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.